MIT Researchers Report Results of Use of BioForce Nanosciences' Nano eNabler Molecular Printer
28 Ottobre 2008 - 3:35PM
Marketwired
BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a leader in
systems integration at the micro and nano scales to create products
for the life sciences, is pleased to announce that researchers at
the Massachusetts Institute of Technology ("MIT") have published
their latest work with the Nano eNabler(TM) molecular printer in
the nanotechnology journal "Small." The manuscript, titled
"Cell-Compatible, Multi-Component Protein Arrays with Subcellular
Feature Resolution" was released online on October 10, 2008, and is
in the October print issue of the journal.
In their paper, Ying Mei, Ph.D. and Daniel Anderson, Ph.D.,
post-doctoral researchers in the laboratory of Professor Robert
Langer, demonstrate the fabrication with the Nano eNabler of micro
scale arrays containing large numbers of single-component and
multiple-component protein spots of varying densities to study the
adhesion and spreading of mouse muscle cells. The researchers
discovered that through use of the Nano eNabler they were able to
create protein arrays which allowed them to align the mouse cells
that had been deposited onto the arrays. This ability to control
the alignment of cells has utility in the growth of organized
cellular structures, an important prelude to future work in the
areas of stem cell differentiation and tissue engineering.
BioForce's Product Manager, Michael Lynch, said, "We are proud
to have our technology validated by such a high-profile lab. This
publication demonstrates the effectiveness of the Nano eNabler for
constructing complex cellular microenvironments. The market's need
for the Nano eNabler is demonstrated by the researchers' comments
in the paper about the Nano eNabler's unique ability to effectively
create arrays containing the desired one to ten microns feature
sizes. Without the Nano eNabler's capabilities, this project, and
the future work to be performed by MIT and other Nano eNabler users
in areas such as stem cell differentiation and tissue engineering,
would not be possible."
On October 23, 2008, Dr. Ying Mei presented the findings
published in their paper through a free BioForce-hosted online
seminar. The title of his webinar presentation was
"Cell-Compatible, Multi-Component Protein Arrays with Subcellular
Feature Resolution" and interested viewers may download a video of
the webinar from the BioForce Resources Library.
For further information about this release please contact Greg
Brown, Chief Financial Officer of BioForce at 515-233-8333 ext.
118, or Rich Kaiser, Investor Relations at 800-631-8127.
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences creates products and solutions for the
life sciences by integrating biological and mechanical systems at
the micro and nano scales. BioForce's flagship product, the Nano
eNabler(TM) molecular printer, gives the Company and its customers
a platform for development and discovery by printing tiny domains
of biological materials on surfaces with nanometer spatial
precision. BioForce technology is being used in areas such as
biosensor functionalization; pattering and cell adhesion; and the
printing of proteins to guide neural cell growth. For more
information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may
be affected by certain risks and uncertainties, including those
risks and uncertainties described in BioForce Nanosciences' most
recent filings with the Securities and Exchange Commission.
BioForce Nanosciences' actual results could differ materially from
such forward-looking statements. BioForce assumes no duty to update
these statements at any future date.
Contacts: Company Contact Gregory D. Brown Chief Financial
Officer 515-233-8333 ext# 118 Email Contact Investor Relations Yes
International Rich Kaiser 800-631-8127
Grafico Azioni BioForce Nanosciences (PK) (USOTC:BFNH)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni BioForce Nanosciences (PK) (USOTC:BFNH)
Storico
Da Dic 2023 a Dic 2024